Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: JNJ.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Johnson & Johnson (JNJ) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

SELL ALL

$254

-5.9%-3.9% incl. dividends

2031

5-Year

NEUTRAL

$294

+8.9%+20.8% incl. dividends

Published batch insight

Valuation Reality Confronts Resilient Healthcare Cash Flow Compounding

There is high consensus that operational execution remains robust across oncology and cardiovascular intervention. However, sharp divergence persists regarding whether an elevated valuation multiple can withstand five percent Treasury yields, biosimilar margin erosion, and ongoing tort liabilities over the forward five-year investment horizon.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist), Superintelligence (Anthropologist), Elon Musk (Visionary), Michael Burry (Vulture), Universal Investor (Polymath), Ray Dalio (Strategist), Machiavelli (Insider), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Johnson & Johnson at the forecast anchor (2026-09-18): $12,082 in five years versus $13,892 for S&P 500 benchmark.

Johnson & Johnson · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.1% net dividend yield for Johnson & Johnson.

Figure: Five-year synthesized consensus value path for Johnson & Johnson compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 269.99 USD1-year price return: -5.86%5-year price return: +8.90%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	262.10	-2.92%	-2.92%	Elevated sovereign yields near five percent trigger institutional profit-taking in high-multiple defensive equities. Multiple compression outweighs solid quarterly operational volume, initiating a necessary valuation reset as flight-to-safety flows stabilize across broader asset markets.
Q1 2027	256.20	-2.25%	-5.11%	Full-year financial guidance confirms revenue crossing the hundred-billion milestone, but conservative outlooks highlight accelerating biosimilar erosion in legacy immunology. Slower forward net income compounding forces a downward recalibration of premium earnings multiples.
Q2 2027	254.57	-0.63%	-5.71%	Progress on claimant voting tallies for the proposed talc settlement reduces tail legal uncertainty, establishing fundamental valuation support. Commercial uptake of next-generation oncology biologics helps cushion residual generic discounting across European markets.
Q3 2027	254.16	-0.16%	-5.86%	Disposal or separation of the orthopaedics franchise clarifies the remaining portfolio profile and financing capacity. Stable cardiovascular procedure volumes balance initial settlement cash disbursements, keeping quarterly price performance tightly contained.
Q4 2027	255.45	+0.51%	-5.38%	Accelerating volume in subcutaneous oncology formulations and specialized catheter platforms lifts quarterly operating margins. Management's capital return commitments and disciplined buybacks reinforce price stability heading into the fiscal year-end close.
Q1 2028	255.38	-0.03%	-5.41%	Initial implementation of federally negotiated drug prices trims gross realizations on exposed biopharmaceutical lines. The market distinguishes top-line volume growth from retained operating cash margins, producing range-bound price action during quarterly consolidation.
Q2 2028	259.43	+1.59%	-3.91%	Positive clinical trial telemetry and expanding international regulatory clearances for interventional cardiovascular platforms support earnings expectations. Maturing launch infrastructure lowers incremental commercialization expenses, driving modest quarterly equity appreciation.
Q3 2028	259.43	+0.00%	-3.91%	Financing sensitivities among hospital procurement budgets temporarily moderate equipment placements. Nevertheless, non-discretionary procedural consumable demand and expanding hematology indications preserve robust underlying cash generation, limiting downside equity drift.
Q4 2028	262.97	+1.37%	-2.60%	The shrinking top-line weight of expired legacy biologics allows newer immunology launches to drive visible consolidated growth. Announcement of the sixty-sixth consecutive dividend raise provides reliable valuation support among conservative institutional income allocators.
Q1 2029	261.84	-0.43%	-3.02%	Expiration of Section 232 tariff carve-outs and statutory price caps introduce temporary margin headwinds. Sell-side models absorb these policy adjustments, prompting brief multiple digestion before operational mitigations take full effect.
Q2 2029	266.02	+1.60%	-1.47%	Domestic manufacturing optimizations absorb trade policy friction while high-margin cell therapy adoption expands globally. Demonstrating earnings durability amidst policy transitions rebuilds institutional confidence, generating measured upward share price momentum.
Q3 2029	268.68	+1.00%	-0.49%	Approaching composition-of-matter patent expirations on cornerstone oncology assets prompt proactive portfolio positioning. Market concerns are partially tempered by high patient retention on proprietary subcutaneous formulations and expanding robotic surgery adoption.
Q4 2029	272.63	+1.47%	+0.98%	Completion of multi-year biopharmaceutical supply-chain restructurings yields tangible manufacturing efficiencies. Annual free cash generation easily covers recurring capital commitments and opportunistic equity repurchases, lifting per-share valuation into year-end.
Q1 2030	275.83	+1.17%	+2.16%	Annual financial reporting showcases consolidated revenue expanding comfortably above historical thresholds with stable operating margins. Steady operational execution proves post-cliff resilience, prompting constructive earnings revisions across fundamental healthcare funds.
Q2 2030	278.19	+0.86%	+3.04%	Broadened international adoption of interventional cardiology devices and robotic surgical systems accelerates MedTech earnings compounding. Expanding high-margin procedural utilization insulates total cash flows from regional pharmaceutical price controls.
Q3 2030	279.74	+0.56%	+3.61%	Demographic aging trends across major developed economies sustain robust baseline volume growth for orthopedic and cardiovascular interventions. Highly predictable operating results support an orderly, low-volatility advance in the quoted equity value.
Q4 2030	283.88	+1.48%	+5.14%	Disciplined balance sheet redeployment through ongoing share cancellations and rising dividend payouts enhances total shareholder return. Deep commercial entrenchment across clinical hospital workflows reinforces the company's defensive competitive moat.
Q1 2031	287.24	+1.18%	+6.39%	Maturing commercial contributions from oral targeted peptides and next-generation bispecific antibodies establish unassailable therapeutic dominance. Sustainable mid-single-digit operating growth validates management's long-term portfolio regeneration strategy.
Q2 2031	290.69	+1.20%	+7.67%	Advanced automated manufacturing facilities lower per-unit biologic production costs, supporting operating profit margins near peak cycle levels. Steady cash conversion maintains robust liquidity, driving gradual equity appreciation toward fair value.
Q3 2031	294.02	+1.14%	+8.90%	The five-year transition cycle concludes with valuation multiples fully normalized near historical medians. High-quality operational earnings growth successfully absorbs past multiple compression, delivering stable capital preservation and reliable distributions.

The base-case investment thesis resolves as an economic tug-of-war between durable business compounding and mechanical multiple compression. Operationally, the enterprise is successfully replacing legacy exclusivity losses through double-digit volume expansion in oncology anchors, newly approved targeted oral peptides, and high-barrier cardiovascular devices, supporting mid-single-digit top-line compounding toward $120 billion by 2031. However, starting valuations near 31x trailing earnings and an equity free cash flow yield below 3% create severe discount-rate vulnerability against persistent 5% risk-free sovereign benchmarks. As multiple normalization toward historical 18x to 20x parameters offsets underlying net income gains, capital appreciation will be muted, leaving dividends and share retirements to deliver the bulk of total shareholder returns.

Key insights

Replacing expiring pharmaceutical exclusivity demands massive operational reinvestment, which dilutes incremental cash conversion even when reported adjusted earnings per share expand steadily.
Policy frictions, specifically statutory Medicare price negotiations and expiring Section 232 tariff carve-outs in early 2029, place a structural ceiling on gross realizations.
Portfolio optimization, including the planned orthopaedics separation, mechanically improves group growth and margin mix, yet cannot fully insulate equity multiples from macroeconomic yield competition.

Deep Dive

Prevailing market sentiment treats the enterprise as an unassailable defensive sanctuary, bidding shares to over thirty times earnings following post-separation restructuring, strong oncology volume, and headline progress on a proposed $5.5 billion talc settlement. This consensus relies on the assumption that non-cyclical healthcare demand and $100 billion in revenue insulate the stock from interest rate gravity, complacently treating rich valuation multiples as permanent.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd materially overestimates valuation durability, creating measurable stock overpricing. The market's blind spot is treating defensive pharmaceutical stability as immune to capital-market discount rates when benchmark Treasuries yield near five percent. Crucially, investors overlook that replacing expiring high-margin biologic rents requires heavy ongoing commercialization expenditure and absorbs statutory price concessions, meaning mid-single-digit operational growth cannot sustain premium multiples once safe-haven flight flows unwind.

Repricing catalyst

The primary convergence catalyst is the disclosure of full-year financial guidance bridges revealing margin dilution from biosimilar discounting and statutory Medicare price concessions, paired with actual settlement cash disbursements. Over the next two to six quarters, institutional allocators comparing mid-single-digit earnings expansion against five percent risk-free sovereign alternatives will rebalance capital out of crowded defensive equities, compelling multiple mean reversion toward historical conglomerate norms.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of sticky inflation, policy rates near four percent, and ten-year Treasury yields near five percent constitutes a decisive valuation headwind. While inelastic somatic healthcare demand completely insulates patient volume from macroeconomic cyclicality, the company's thin free cash flow yield leaves equity valuation acutely exposed to discount-rate competition from sovereign debt.

Published consensus context

Advisor disagreement

The decisive debate centers on valuation elasticity versus operational durability. One perspective argues that paying 31x trailing earnings for a five percent revenue grower during a five percent Treasury regime guarantees severe capital destruction as multiples mean-revert. The opposing thesis contends that superior oncology execution, cardiovascular device integration, and litigation ring-fencing justify a durable scarcity premium that cushions the multiple. Resolving this disagreement requires observing full-year 2027 gross margin realizations and checking whether organic sales growth exceeds six percent as Stelara biosimilar discounts accelerate.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Oncology and hematology franchise expansion: Commercial scaling of Darzalex, including rapid conversion to subcutaneous Faspro formulations, combined with earlier-line adoption of Carvykti cell therapy and bispecific antibodies, secures dominant market share in hematologic malignancies. This clinical execution generates durable, high-margin biologic cash flows exceeding $22 billion annually, successfully backfilling off-patent revenue voids. Expected impact: +18%.
Cardiovascular MedTech integration synergies: Strategic integration of Shockwave Medical and Abiomed into the global electrophysiology infrastructure establishes commanding chokepoints in intravascular lithotripsy and mechanical circulatory support. High procedural switching costs and non-deferrable clinical interventions protect segment gross margins above 70%, accelerating MedTech organic top-line contributions toward seven percent annually. Expected impact: +13%.
Talc litigation liability ring fencing: Advancing a consensual $5.5 billion settlement covering approximately 76,000 ovarian cancer claimants systematically transforms open-ended tort liabilities into predictable, amortized cash disbursements. Achieving final judicial confirmation eliminates an existential institutional governance discount, releasing restricted balance-sheet reserves and restoring long-term credit stability without imperiling ongoing operations. Expected impact: +11%.
Fortress balance sheet capital compounding: Armed with a pristine AAA credit profile and annual free cash flow exceeding $19 billion, management executes disciplined capital allocation. Consistent dividend increases spanning over six decades paired with programmatic share repurchases retiring roughly one percent of float annually systematically cushion per-share intrinsic value through restrictive credit cycles. Expected impact: +9%.

Top frictions and headwinds

Valuation multiple mean reversion drag: Trading at an anomalous multiple above 31x trailing earnings with a sub-3% free cash flow yield creates an unsustainable spread against 5% sovereign Treasury yields. As defensive safe-haven crowding subsides, mechanical multiple mean reversion toward historical 18x to 20x parameters exerts severe downward pressure on quoted equity prices. Expected impact: -20%.
Stelara biosimilar patent cliff erosion: Accelerating biosimilar penetration against cornerstone immunology biologic Stelara across North American and European formularies strips billions in high-margin cash flow. Price discounts exceeding forty percent create an ongoing top-line operational drag that newer pipeline assets must expend substantial commercial capital to replace. Expected impact: -13%.
Statutory drug price negotiation mandates: Federal price negotiation frameworks under the Inflation Reduction Act enforce statutory discounts across major biopharma therapies, including upcoming cycles affecting key cardiovascular and oncology treatments. These mandatory concessions compress domestic gross-to-net realizations, placing an unyielding structural ceiling on pharmaceutical operating margin expansion. Expected impact: -10%.
Trade policy and tariff expiry: Proclamation 11020 pharmaceutical tariff exemptions tied to onshoring and most-favored-nation pricing agreements carry a firm expiration date on January 20, 2029. The approaching expiration threatens import duty reversions while enforced international reference pricing structurally erodes net realizations across core biopharmaceutical franchises. Expected impact: -8%.

Tail risks

Talc settlement collapse and litigation: Claimant balloting failing to achieve the mandatory 95% threshold would void the proposed $5.5 billion settlement, remanding tens of thousands of active tort claims back to state jury dockets. Exposure to runaway punitive verdicts exceeding billions in single awards would force emergency litigation reserve additions, impairing net earnings and triggering severe multiple de-rating. Probability: +30%. Expected impact: -21%.
Commercial price control legislative expansion: Bipartisan federal legislation expanding mandatory statutory price negotiation caps from Medicare into private employer commercial insurance formularies would permanently dismantle domestic biopharma gross realizations. Slicing billions directly from core oncology and immunology revenues would structurally reduce return on invested capital and induce violent equity derating. Probability: +22%. Expected impact: -19%.

Tail opportunities

Oral immunology peptide market sweep: Pivotal Phase 3 readouts and regulatory label expansions establishing oral IL-23 inhibitor icotrokinra as first-line therapy across inflammatory bowel diseases would transform autoimmune treatment paradigms. Dislodging injectable biologics with shelf-stable oral convenience would expand addressable patient volume threefold, unlocking over $8 billion in peak annual sales and driving substantial operating margin accretion. Probability: +32%. Expected impact: +19%.
Ottava surgical robotics commercial ascendancy: Securing rapid commercial hospital network standardization for the Ottava soft-tissue robotic platform would break entrenched incumbent surgical monopolies. Capitalizing on Ethicon's vast hospital footprint to drive recurring proprietary instrument and digital consumable sales would accelerate MedTech division growth into double digits, triggering broad institutional multiple expansion across the enterprise. Probability: +28%. Expected impact: +15%.

What to monitor

Thesis watchpoints

-- Full-year adjusted operational revenue growth maintaining above 5.5% through mid-2027 confirms pipeline substitution is successfully overpowering legacy patent expiration drag.

Key insights

Claimant participation on the proposed talc settlement falling below the mandatory 95% threshold by mid-2027 reignites uncapped mass-tort trial liabilities.
Consolidated pharmaceutical gross margin dipping below 66.5% during fiscal 2027 signals severe net price erosion from statutory Medicare negotiations.

Company Financial Analysis

Johnson & Johnson Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The enterprise is demonstrating genuine top-line resilience, with annual revenues surpassing the milestone of one hundred billion dollars behind robust volume growth in flagship oncology medicines and cardiovascular devices. These expanding franchises have effectively absorbed the steep revenue drop in older blockbuster treatments like Stelara following the arrival of low-cost biosimilars. However, reported headline profits continue to be distorted by volatile legal reserves and acquisition amortizations. Beneath these accounting swings, underlying owner earnings are compounding at a stable mid-single-digit pace, backed by around twenty-two billion dollars in reconstructed trailing free cash flow that provides solid foundation for operations.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 94.2B	USD 26.8B	USD 19.7B
2024	USD 88.8B	USD 14.1B	USD 19.8B
2023	USD 85.2B	USD 35.2B	USD 18.2B
2022	USD 80B	USD 17.9B	USD 17.2B
2021	USD 78.7B	USD 20.9B	USD 19.8B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	18.8x	TTM	Native	USD / USD
2024	25.0x	TTM	Native	USD / USD
2023	10.8x	TTM	Native	USD / USD
2022	26.2x	Annual	Native	USD / USD
2021	21.9x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Operating margins have shown healthy resilience near twenty-seven percent, supported by corporate streamlining following the consumer health spin-off and favorable product mix toward high-margin cancer therapies. Disciplined administrative cost control has helped protect overall profitability despite persistent inflation in hospital labor and specialized supply chains. Looking ahead, maintaining gross margins near sixty-eight percent will become increasingly challenging. Severe biosimilar price discounting on legacy treatments alongside mandatory government Medicare price caps represent structural headwinds that sales volume gains can only partially offset, keeping a tight ceiling on further profit margin expansion.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 25.6B	27.2%	28.5%
2024	USD 22.1B	24.9%	15.8%
2023	USD 21.9B	25.7%	41.3%
2022	USD 21B	26.3%	22.4%
2021	USD 20.9B	26.6%	26.5%

Balance sheet and leverage

AI Review

The enterprise preserves an elite AAA-rated balance sheet characterized by conservative financial leverage, a debt-to-equity ratio of 0.59, and interest coverage exceeding thirty-four times operating earnings. This pristine solvency profile allows management to easily absorb major acquisitions and maintain debt service without facing credit market stress. Nevertheless, significant resources are already earmarked for pending legal commitments. While the proposed five-point-five billion dollar talc settlement is well within the company's annual free cash flow capacity, funding these multi-year payouts and potential tariff-related onshoring investments will temporarily limit excess cash available for aggressive share repurchases.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 47.9B	USD 20.1B	USD 28.2B net debt	1.03x
2024	USD 36.6B	USD 24.5B	USD 12.5B net debt	1.11x
2023	USD 29.3B	USD 22.9B	USD 7.5B net debt	1.16x
2022	USD 39.6B	USD 22.3B	USD 26.8B net debt	0.99x
2021	USD 33.8B	USD 31.6B	USD 19.3B net debt	1.35x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management maintains disciplined capital spending, directing roughly five percent of annual revenue into modernizing advanced biologic production facilities and precision medical device plants. Rather than overspending on excess physical factories, capital deployment has deliberately prioritized targeted external acquisitions like Shockwave Medical to secure proven, high-margin technologies. This capital allocation posture allows the company to replace expiring patent revenue without overextending its operational budget. The company's multi-billion-dollar domestic investment commitments focus on high-return cell therapies and surgical robotics, which should generate reliable long-term cash flow while safeguarding overall returns on invested capital.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 4.8B	USD 14.7B
2024	USD 4.4B	USD 17.2B
2023	USD 4.5B	USD 15B
2022	USD 4B	USD 14.1B
2021	USD 3.7B	USD 14.3B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	SELL_ALL	-205	-4.6%	Not available	ORIGINAL
5Y	NEUTRAL	-4	+17.5%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	253.79	262.66	264.59	14
+6M	March 18, 2027	243.64	255.93	272.53	14
+9M	June 18, 2027	243.87	253.05	277.98	14
+1Y	September 18, 2027	236.56	252.17	269.86	14
+15M	December 18, 2027	229.44	252	280.42	14
+18M	March 18, 2028	222.55	250.99	286.03	14
+21M	June 18, 2028	218.1	253.88	294.61	14
+2Y	September 18, 2028	215.92	254.37	288.72	14
+27M	December 18, 2028	215.92	257.09	294.5	14
+30M	March 18, 2029	218.08	256.27	289.21	14
+33M	June 18, 2029	220.26	260	294.81	14
+3Y	September 18, 2029	218.06	262.13	297.02	14
+39M	December 18, 2029	220.24	265.6	305.93	14
+42M	March 18, 2030	224.64	268.56	308.99	14
+45M	June 18, 2030	226.89	271.02	309.79	14
+4Y	September 18, 2030	226.89	272.77	312.89	14
+51M	December 18, 2030	229.16	276.4	317.98	14
+54M	March 18, 2031	231.45	279.43	324.33	14
+57M	June 18, 2031	233.76	282.49	330.82	14
+5Y	September 18, 2031	233.76	285.6	337.44	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The common causal pattern across all submissions is that commercial operations are expanding at five to six percent annually, driven by oncology volume and cardiovascular MedTech integration, but face an acute multiple compression headwind. An elevated trailing price-to-earnings ratio and a thin free cash flow yield leave the asset vulnerable to capital reallocation when risk-free sovereign yields approach five percent. Submissions with the highest evidentiary quality meticulously reconcile official cash conversion, separate biosimilar replacement revenue from incremental earnings, and incorporate verified policy timelines, including statutory Medicare negotiations and Section 232 tariff carve-outs expiring in early 2029. Lower weights are assigned to reports that rely on rhetorical assertions or project catastrophic derating without accounting for pristine balance-sheet flexibility and steady share retirements. The strongest credible contrarian insight confirms that defensive scarcity has driven an equity multiple overshoot that requires multi-year earnings compounding to digest.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight13.5/100

Highest evidentiary rigor among the submissions, verifying official SEC filings, reconciling trailing free cash flows, and incorporating specific regulatory approvals like the targeted oral peptide. Carefully separates replacement revenue from incremental growth.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight11.5/100

Exceptional evidentiary quality incorporating granular primary documentation on Section 232 tariff carve-outs, DePuy divestiture pathways, and talc settlement structures. The causal chain connecting policy expiries to net realized price erosion is highly persuasive.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight9.6/100

Offers forensic scrutiny of GAAP versus non-GAAP reconciliations, litigation contingency accounting, and subcutaneous formulation defenses against biosimilar entry. Grounds intermediate price targets in audited financial milestones and concrete clinical launch timelines.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight7.7/100

Presents rigorous economic reasoning regarding terminal cash flow replacement and the drag of elevated Treasury yields against thin equity risk premia. Balances operational pipeline scale across hematology with legitimate multiple compression risks over the forecast horizon.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight7.7/100

Constructs a balanced view of cardiovascular MedTech integration offsetting patent expirations. Clearly articulates the negative equity risk premium while appropriately modeling moderate recovery as newer oncology and immunology assets reach commercial maturity.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight7.7/100

Delivers an incisive forensic dissection of unhedged state-level tort exposure and multiple mean reversion. Offers essential downside risk modeling, though its projection of persistent net multiple deflation discounts management's demonstrated ability to convert operating earnings.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight7.7/100

Provides strong institutional analysis of commercial scale, predatory balance sheet deployment, and hospital switching costs. While appropriately cautious on near-term rate headwinds, it builds a well-reasoned operational compounding scenario through 2031.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight6.7/100

Strong analytical focus on procurement power, statutory Medicare negotiation dynamics, and institutional capital flows. Effectively demonstrates how operational gains can be neutralized by regulatory price friction over a multi-year forecast horizon.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight5.8/100

Effectively models macro discount rate transmission onto equity multiples in a restrictive monetary regime. While its debt-cycle framing is sound, it somewhat underestimates operating margin leverage from post-separation cost rationalization.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight5.8/100

Provides a disciplined owner-earnings framework contrasting six percent organic compounding against elevated starting valuations. The analysis is causally sound but relies on standard valuation heuristics without exploring specific regulatory tariff mechanics.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight4.8/100

Detailed evaluation of gross margin degradation resulting from biosimilar penetration and hospital budgeting caps. Well-structured economically, though its path assumes prolonged multiple stagnation that underweights pipeline commercialization upside.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight3.8/100

This analysis provides a useful critique of multiple vulnerability and patent cliff dynamics. However, its assumption of an unmitigated valuation collapse to seventeen times earnings understates the cash cushion provided by recent oncology and cardiovascular acquisitions.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight3.8/100

Correctly highlights the disconnect between a sub-three percent free cash flow yield and prevailing Treasury rates. However, its path models a severe initial price decline that slightly overstates biosimilar margin destruction.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight3.8/100

Presents a forceful contrarian case on defensive crowding and bond-proxy mispricing. While its behavioral insights are compelling, the projected price trajectory relies on extreme multiples de-rating that discounts balance-sheet cash deployment.

Skip to references

Research Provenance

References & Context

This Johnson & Johnson consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 119 deduplicated sources retained for this batch.

01CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation | CMScms.gov
02https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/a2026q1exhibit993.htm?utm_source=openaisec.gov
03jnj-20260628sec.gov
04Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigationjnj.com
05Johnson & Johnson reports Q2 2026 results, raises 2026 outlookjnj.com
06Johnson & Johnson Is Near a Record High. Is There Still Room to Run? - 24/7 Wall St.247wallst.com
07Trump Administration Announces Section 232 Tariffs on Pharmaceuticals | Brownsteinbhfs.com
08Johnson & Johnson reports Q2 2026 results, raises 2026 outlook - BioSpacebiospace.com
09U.S. Pharma Tariffs And MFN Become Law After April 2 Updateclinicalleader.com
10J&J to spin off orthopedics business, sees 2026 sales growth of over 5%cnbc.com
11JNJ Stock Quote Price and Forecast | CNNcnn.com
12Talcum Powder Settlement | $5.5 Billion Johnson & Johnson Offerconsumernotice.org
13A New Round in US Pharma Tariffs: What's at Play? - DCAT Value Chain Insightsdcatvci.org
14Johnson & Johnson Talcum Powder Lawsuit [August 2026 ]drugwatch.com
15J&J move to spin off orthopedics unit is 'all about shrinking to grow faster,' exec saysfiercebiotech.com

And 104 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.